Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7B

3 mins read
56 views

Deals and Financings

Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for its next-gen PARP1 inhibitor to Germany’s Merck KGaA (OTCPK:MKGAF) for a $170 million upfront payment and up to $1.5 billion in milestones, plus royalties (see story

Read the full article here

Leave a Reply

Your email address will not be published.

Previous Story

Epic Games is the latest to take on Google in court over antitrust charges

Next Story

Hedge funds caught in crowded trades suffered in Thursday’s stock rally -Goldman Sachs

Latest from News